CORRECTION

When the editorial “Is There Really Nothing New Under the Sun? Is Low-Dose Ketamine a Fast-Acting Antidepressant Simply Because It Is An Opioid?,” by Mark S. George (doi:10.1176/appi.ajp.2018.18070800) was published online on August 29, 2018, it included statements about ketamine and NMDA receptor activation; ketamine is an NMDA-R antagonist.

The third sentence of the second paragraph should read “They asked this question in part because the other main pharmacological action of ketamine, N-methyl-d-aspartate (NMDA) receptor antagonism, has largely failed to emerge as the necessary mechanism of action for ketamine’s antidepressant effects.”

The seventh sentence of the third paragraph should read “It may be that ketamine’s effects require combined opioid receptor activation and NMDA receptor antagonism.”

The article was reposted with these sentences corrected on September 21, 2018.